Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents

In the past three decades, a great interest has arisen in the use of immunoglobulins as therapeutic agents. In particular, since the approval of the first monoclonal antibody Rituximab for B cell malignancies, the progress in the antibody-related therapeutic agents has been incremental. Therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: van Tetering, Geert, Evers, Mitchell, Chan, Chilam, Stip, Marjolein, Leusen, Jeanette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768499/
https://www.ncbi.nlm.nih.gov/pubmed/33333967
http://dx.doi.org/10.3390/antib9040070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768499/
https://www.ncbi.nlm.nih.gov/pubmed/33333967
http://dx.doi.org/10.3390/antib9040070

Ejemplares similares